Affiliation:
1. Department of Life Science, Dongguk University-Seoul, Goyang 10326, Republic of Korea
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is caused by lipid accumulation within the liver. The pathogenesis underlying its development is poorly understood. Benzo[a]pyrene (B[a]P) is a polycyclic aromatic hydrocarbon and a group 1 carcinogen. The aryl hydrocarbon receptor activation by B[a]P induces cytochrome P450 (CYP) enzymes, contributing to hepatic lipid accumulation. However, the molecular mechanism through which the B[a]P-mediated induction of CYP enzymes causes hepatic lipid accumulation is unknown. This research was conducted to elucidate the role of CYP1B1 in regulating B[a]P-induced lipid accumulation within hepatocytes. B[a]P increased hepatic lipid accumulation, which was mitigated by CYP1B1 knockdown. An increase in the mammalian target of rapamycin (mTOR) by B[a]P was specifically reduced by CYP1B1 knockdown. The reduction of mTOR increased the expression of autophagic flux-related genes and promoted phagolysosome formation. Both the expression and translocation of TFE3, a central regulator of lipophagy, were induced, along with the expression of lipophagy-related genes. Conversely, enhanced mTOR activity reduced TFE3 expression and translocation, which reduced the expression of lipophagy-related genes, diminished phagolysosome production, and increased lipid accumulation. Our results indicate that B[a]P-induced hepatic lipid accumulation is caused by CYP1B1-induced mTOR and the reduction of lipophagy, thereby introducing novel targets and mechanisms to provide insights for understanding B[a]P-induced MASLD.
Funder
National Research Foundation of Korea
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference60 articles.
1. Pathology of Nonalcoholic Fatty Liver Disease;Brunt;Nat. Rev. Gastroenterol. Hepatol.,2010
2. Tripodi, A., Lombardi, R., Primignani, M., La Mura, V., Peyvandi, F., and Fracanzani, A.L. (2022). Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (MASLD): Causes and Consequences. Biomedicines, 10.
3. The Role of Lipophagy in the Development and Treatment of Non-Alcoholic Fatty Liver Disease;Grefhorst;Front. Endocrinol.,2021
4. Global Epidemiology of Nonalcoholic Fatty Liver Disease—Meta-analytic Assessment of Prevalence, Incidence, and Outcomes;Younossi;Hepatology,2016
5. Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Current Progresses and Challenges;Teng;J. Clin. Transl. Hepatol.,2022